+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service



A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service



Journal of the American Academy of Dermatology 80(6): 1796-1798




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066501791

Download citation: RISBibTeXText

PMID: 30771422

DOI: 10.1016/j.jaad.2019.02.014


Related references

Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting. Giornale Italiano di Dermatologia e Venereologia 154(2): 166-169, 2019

Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience. Rheumatology 57(3): 578-580, 2018

Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. Journal of Rheumatology 43(6): 1063-1067, 2016

Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis. Current Rheumatology Reviews 15(3): 234-237, 2019

Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. Scandinavian Journal of Rheumatology 39(4): 303-309, 2010

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology 2018:, 2018

Budget Impact Analysis of Apremilast In Patients With Psoriatic Arthritis In The Italian Setting. Value in Health 18(7): A645, 2015

Cost-Utility Analysis of Apremilast for The Treatment of Psoriatic Arthritis In The Italian Setting. Value in Health 18(7): A646, 2015

The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatologic Clinics 22(4): 449-59 Ix, 2004

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Annals of the Rheumatic Diseases 77(5): 690-698, 2018

THU0141A Non-Interventional Clinical Study Evaluating The Use of Golimumab in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA), and Ankylosing Spondylitis (AS) in A Real-Life Setting in Germany. Annals of the Rheumatic Diseases 75(Suppl 2): 232.2-232, 2016

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. Rmd Open 1(1): E000181, 2015

Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. Journal of the European Academy of Dermatology and Venereology 31(6): 1021-1028, 2017

SAT0403Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis. Annals of the Rheumatic Diseases 73(Suppl 2): 740.1-740, 2014

SAT0562Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Nave Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4):. Annals of the Rheumatic Diseases 74(Suppl 2): 863.2-864, 2015